Top Injectable Manufacturer in Bhutan – Reliable Pharmaceutical Solutions
Last Updated: September 12, 2026
TL;DR: Bhutan rewrote its medicines rulebook seven months ago. The Bhutan Medicines Rules and Regulation 2025 came into force on 21 February 2026 and superseded the 2019 edition, and the regulator has not been the Drug Regulatory Authority since 2022 — it is the Bhutan Food and Drug Authority. Bhutan names the Indian Pharmacopoeia as an accepted standard and trades with India duty-free. What it does not do is give Indian regulatory approval any reliance benefit.
Key Takeaways
The Bhutan Medicines Rules and Regulation 2025 took effect on 21 February 2026, superseding the 2019 edition. Any guidance still naming the Drug Regulatory Authority describes a regime that no longer exists.
The abridged route keys off WHO-Listed Authority status, transitional WLA status or WHO prequalification, and names no agency at all. CDSCO's transitional listing is scoped to vaccines, so it earns an Indian injectable nothing here.
The Indian Pharmacopoeia is named — one of six pharmacopoeias accepted by the current registration guideline. That recognition sits in guidance, not in the Act or the Rules, which name none.
A Bhutanese entity must hold the Market Authorization; a foreign manufacturer cannot. Free trade with India removes the tariff and the currency risk, not the local-partner requirement.
Introduction: What an Injectable Manufacturer in Bhutan Has to Prove
Every market in this series opens with the same question — does the country name the foreign regulators whose decisions it will lean on, and is India's CDSCO among them? Bhutan answers inside a rulebook seven months old. The Bhutan Medicines Rules and Regulation 2025 came into force on 21 February 2026 and expressly superseded the 2019 edition. The regulator changed earlier and more quietly: the Drug Regulatory Authority was folded into the Bhutan Food and Drug Authority under the Civil Service Reform Act of Bhutan 2022.
Read what the new regime says rather than what it suggests. The abridged route opens only where a product is registered by a WHO-Listed Authority or a transitional WLA, or prequalified by WHO — and the guideline names no authority anywhere. CDSCO sits on WHO's transitional list for vaccines, not for medicines, so an Indian approval carries an injectable through none of those limbs. The standard route stays fully open; it simply confers no shortcut.
What Sets a World-Class Injectable Manufacturer in Bhutan Apart
The distinction that matters most here is between a reliance test and a certificate test. Bhutan's standard route asks for proof of foreign approval — a country-of-origin marketing authorisation, an assessment report, or a Certificate of a Pharmaceutical Product in WHO format. An Indian manufacturer satisfies that comfortably, and it buys no abridgement. The one genuine shortcut open to an Indian plant is a BFDA audit of the site itself, graded at the authority's top level, and that route is restricted to medicines on Bhutan's essential medicines list.
The second thing worth knowing is that Bhutan names the Indian Pharmacopoeia. The current registration guideline accepts six pharmacopoeias — British, United States, Indian, International, Japanese and European — and requires the edition relied on to have issued within the last five years. Keep it in proportion, though: neither the Medicines Act nor the Rules names any pharmacopoeia, so the recognition rests on a guideline the authority can revise without legislation.
Quality Systems Behind Every Sterile Injectable We Ship to Bhutan
The dossier Bhutan asks for is largely the dossier a serious sterile plant already generates. Farbe Firma manufactures under WHO-GMP certification in ISO Class 5 filling environments, with validated aseptic process simulation, environmental monitoring and container-closure integrity testing. Release testing runs on HPLC and GC against USP, BP, IP or EP monographs, with LAL for bacterial endotoxins and Karl Fischer for moisture in lyophilised vials. Stability follows ICH Q1A with Q1B photostability. Dossiers are built in CTD structure with ACTD available — Bhutan accepts either.
Two details change how the file is assembled. A Site Master File in WHO format is mandatory for foreign manufacturers and is not asked of domestic ones, so it is a workstream to schedule rather than an afterthought. And Bhutan waives bioequivalence data for simple aqueous intravenous solutions and powders for reconstitution, which covers much of a sterile injectable portfolio. On storage conditions we found no published Bhutanese climatic-zone assignment, and therefore claim none.
Working out whether Bhutan is reachable for your product? Talk to our regulatory team
Why Farbe Firma is the Trusted Injectable Manufacturer in Bhutan for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Bhutan we can build the CTD or ACTD dossier, supply the WHO-format CPP and Site Master File, and generate the stability and release data the file needs. What we cannot do is hold the registration: the Rules restrict applications to a Bhutan-based manufacturer, a licensed wholesale pharmacy or a government procurement agency. We hold no Bhutanese registration and recommend no partner we have not verified.
The commercial frame is unusually favourable and widely misdescribed. The India–Bhutan Agreement on Trade, Commerce and Transit establishes a free trade regime, and bilateral trade is invoiced in Indian Rupees at par with the Ngultrum — no tariff line to negotiate and no currency exposure. Note what that does not mean. Bhutan is a WTO observer rather than a member, so it carries no TRIPS obligations, and free trade in goods does not license entry of an unregistered medicine.
The numbers are small, and being straight about them matters more than the size. Population was 791,524 in 2024 on World Bank figures; current health expenditure was 4.42% of GDP in 2023 and US$162 per head, putting the entire national health budget near US$128 million. Government financing rose to 66.65% in 2023 while external financing fell to 6.44% — a donor unwind, not a spending surge. Bhutan's own customs data put India at 75.1% of pharmaceutical imports in 2024, so the familiar claim of total dependence overstates it. We will not print a market-size figure: the two available sources differ by nearly twice.
Explore Farbe Firma: Products / Global Reach / About Us
Frequently Asked Questions (FAQ)
Does Bhutan recognise India's CDSCO or Indian regulatory approval?
Not for reliance purposes. The abridged route turns on WHO-Listed Authority status, transitional WLA status or WHO prequalification and names no agency, while CDSCO's transitional listing is scoped to vaccines rather than medicines. What Bhutan does accept from India is proof of foreign approval — a country-of-origin marketing authorisation or a WHO-format Certificate of a Pharmaceutical Product. That is a requirement about document format, not about which regulator signed it.
Is the Indian Pharmacopoeia accepted in Bhutan?
Yes — one of the few markets in this series where the answer is a clean yes. The current registration guideline lists six acceptable pharmacopoeias and the Indian Pharmacopoeia is among them, provided the edition relied on issued within the last five years. The qualification worth carrying is that neither the Medicines Act nor the Rules names any pharmacopoeia, so the recognition is guideline-level and revisable by the authority.
Does a foreign manufacturer need a local partner in Bhutan?
Yes. The Rules restrict applications to a Bhutan-based manufacturer, an authorised sale-and-distribution premises or a government agency, and the standard authorisation letter requires the holder to have an office in Bhutan, naming it sole dealer and accountable for the product. One point has changed: since February 2026 an importer that is not the authorisation holder may import for sale with a no-objection certificate from that holder.
What does registration cost in Bhutan, and how long does it take?
Both answers are currently published twice, differently, by the same regulator. The fee schedule in the 2025 Rules sets a single Nu. 2,000 market-authorisation fee, while the authority's own FAQ page still shows Nu. 500 plus Nu. 1,500 from the pre-merger era. On timing, the guidelines give a 60-day turnaround that runs on a stop-clock and pauses for every query round, while the same FAQ says two to three months. Confirm both directly with BFDA.
What actually controls an injectable consignment arriving in Bhutan today?
The import authorisation, issued per consignment rather than per product. It covers a single import — six months for an unregistered product, and a year or the remaining registration validity for a registered one — and the current schedule prices it at Nu. 200. Narcotics and psychotropics run on a separate and stricter track through a different division, needing a fresh authorisation for every shipment. A supplier describing one standing import licence is reading something that is not there.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments